Patents Assigned to ModernaTX, Inc.
  • Combination HMPV/RSV RNA vaccines
    Patent number: 11872278
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 16, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto
    Patent number: 11866475
    Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Leif Karlsson Parinder, Regina Desirée Fritsche Danielson, Kenny Mikael Hansson, Li Ming Gan, Jonathan Clarke, Ann-Charlotte Eva Egnell, Kenneth Randall Chien
  • Analytical HPLC methods
    Patent number: 11866696
    Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: William Issa, Meredith Packer
  • Trinucleotide mRNA cap analogs
    Patent number: 11866754
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Matthew Stanton, Edward John Miracco
  • INFLUENZA VACCINE
    Publication number: 20240000917
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Application
    Filed: May 24, 2023
    Publication date: January 4, 2024
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
    Patent number: 11859215
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 2, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn
  • High fidelity in vitro transcription
    Patent number: 11851694
    Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 26, 2023
    Assignee: ModernaTX, Inc.
    Inventors: David Mauger, Vladimir Presnyak, Amy E. Rabideau, Iain Mcfadyen
  • Ribonucleic acid purification
    Patent number: 11845772
    Abstract: Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2?deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: December 19, 2023
    Assignee: ModernaTX, Inc.
    Inventors: William Joseph Issa, John Grant Aunins, Stephane Bancel
  • RESPIRATORY SYNCYTIAL VIRUS VACCINE
    Publication number: 20230390379
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 7, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • RESPIRATORY VIRUS NUCLEIC ACID VACCINES
    Publication number: 20230381301
    Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPIV3) F protein.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 30, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)
    Publication number: 20230374079
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: August 4, 2023
    Publication date: November 23, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
  • MULTI-PROLINE-SUBSTITUTED CORONAVIRUS SPIKE PROTEIN VACCINES
    Publication number: 20230355743
    Abstract: The disclosure provides coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Guillaume Stewart-Jones, Mihir Metkar, Vladimir Presnyak
  • SEXUALLY TRANSMITTED DISEASE VACCINES
    Publication number: 20230346907
    Abstract: The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 2, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • SARS-COV-2 MRNA DOMAIN VACCINES
    Publication number: 20230346914
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.
    Type: Application
    Filed: February 6, 2021
    Publication date: November 2, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Guillaume Stewart-Jones, Andrea Carfi, Sayda Mahgoub Elbashir, Mihir Metkar
  • Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
    Patent number: 11801227
    Abstract: The invention relates to mRNA therapy for the treatment of cystic fibrosis. mRNAs for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR), isoforms thereof, functional fragments thereof, and fusion proteins comprising CFTR. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of CFTR expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient CFTR activity in subjects.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 31, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Kerry Benenato, Stephen Hoge, Iain McFadyen, Vladimir Presnyak, Paolo Martini, Ellalahewage Sathyajith Kumarasinghe
  • Polynucleotides encoding anti-chikungunya virus antibodies
    Patent number: 11802146
    Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 31, 2023
    Assignees: ModernaTX, Inc., Vanderbilt University
    Inventors: Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
  • RESPIRATORY VIRUS IMMUNIZING COMPOSITIONS
    Publication number: 20230338506
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: January 29, 2021
    Publication date: October 26, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Christine Shaw, Guillaume Stewart-Jones, Elisabeth Narayanan, Vladimir Presnyak, Sayda Mahgoub Elbashir
  • RNA formulations
    Patent number: 11786607
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 17, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Joseph Schariter, Charles Bowerman, Michael H. Smith, Yan Xia
  • BROAD SPECTRUM INFLUENZA VIRUS VACCINE
    Publication number: 20230310576
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 5, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)
    Publication number: 20230303632
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: February 28, 2023
    Publication date: September 28, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir